Characterization of amyloid β peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry

Journal of Proteome Research

Volumn 6, Issue 11, 2007, Pages 4433-4439

  Portelius, Erik ^a   Tran, Ai Jun ^a   Andreasson, Ulf ^a   Persson, Rita ^a   Brinkmann, Gunnar ^a   Zetterberg, Henrik ^a   Blennow, Kaj ^a   Westman Brinkmalm, Ann ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

amyloid; Alzheimer's disease; Cerebrospinal fluid; Immunoprecipitation; LC MS MS; LTQ FT; MALDI TOF MS

Indexed keywords

AMYLOID BETA PROTEIN;

ARTICLE; CEREBROSPINAL FLUID; IMMOBILIZATION; IMMUNOPRECIPITATION; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AUTOMATION; CELL CULTURE TECHNIQUES; CEREBROSPINAL FLUID; CHROMATOGRAPHY, LIQUID; DATABASES, PROTEIN; HUMANS; IMMUNOPRECIPITATION; IMMUNOTHERAPY; MASS SPECTROMETRY; PEPTIDES; PROTEIN ISOFORMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 36348970121     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0703627     Document Type: Article

References (36)

1. Blennow, K.; de Leon, M. J.; Zetterberg, H. Alzheimer's disease. Lancet 2006, 368 (9533), 387-403.
2. Selkoe, D. J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 2004, 6 (11), 1054-1061.
3. Kang, J.; Lemaire, H. G.; Unterbeck, A.; Salbaum, J. M.; Masters, C. L.; Grzeschik, K. H.; Multhaup, G.; Beyreuther, K.; Muller-Hill, B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325 (6106), 733-736.
4. Ling, Y.; Morgan, K.; Kalsheker, N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int. J. Biochem. Cell Biol. 2003, 35 (11), 1505-1535.
5. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81 (2), 741-766.
6. Vardy, E. R.; Catto, A. J.; Hooper, N. M. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol. Med. 2005, 11 (10), 464-472.
7. Vassar, R.; Bennett, B. D.; Babu-Khan, S.; Kahn, S.; Mendiaz, E. A.; Denis, P.; Teplow, D. B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M. A.; Biere, A. L.; Curran, E.; Burgess, T.; Louis, J. C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286 (5440), 735-741.
8. Haass, C.; Hung, A. Y.; Schlossmacher, M. G.; Teplow, D. B.; Selkoe, D. J. beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J. Biol. Chem. 1993, 268 (5), 3021-3024.
9. Haass, C.; Schlossmacher, M. G.; Hung, A. Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B. L.; Lieberburg, I.; Koo, E. H.; Schenk, D.; Teplow, D. B.; et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992, 359 (6393), 322-325.
10. Black, R. A.; White, J. M. ADAMs: focus on the protease domain. Curr. Opin. Cell Biol. 1998, 10 (5), 654-659.
11. Yang, P.; Baker, K. A.; Hagg, T. The ADAMs family: coordinators of nervous system development, plasticity and repair. Prog. Neurobiol. 2006, 79 (2), 73-94.
12. Allinson, T. M.; Parkin, E. T.; Turner, A. J.; Hooper, N. M. ADAMs family members as amyloid precursor protein alpha-secretases. J. Neurosci. Res. 2003, 74 (3), 342-352.
13. Gowing, E.; Roher, A. E.; Woods, A. S.; Cotter, R. J.; Chaney, M.; Little, S. P.; Ball, M. J. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J. Biol. Chem. 1994, 269 (15), 10987-10990.
14. Lalowski, M.; Golabek, A.; Lemere, C. A.; Selkoe, D. J.; Wisniewski, H. M.; Beavis, R. C.; Frangione, B.; Wisniewski, T. The " nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J. Biol. Chem. 1996, 271 (52), 33623-33631.
15. Andreasson, U.; Portelius, E.; Andersson, M. E.; Blennow, K.; Zetterberg, H. Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomarkers Med. 2007, 1 (1), 59-78.
16. Cleary, J. P.; Walsh, D. M.; Hofmeister, I. J.; Shankar, G. M.; Kuskowski, M. A.; Selkoe, D. J.; Ashe, K. H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 2005, 8 (1), 79-84.
17. Lesne, S.; Koh, M. T.; Kotilinek, L.; Kayed, R.; Glabe, C. G.; Yang, A.; Gallagher, M.; Ashe, K. H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440 (7082), 352-357.
18. Morgan, C.; Colombres, M.; Nunez, M. T.; Inestrosa, N. C. Structure and function of amyloid in Alzheimer's disease. Prog. Neurobiol. 2004, 74 (6), 323-349.
19. Wang, S. S.; Becerra-Arteaga, A.; Good, T. A. Development of a novel diffusion-based method to estimate the size of the aggregated Abeta species responsible for neurotoxicity. Biotechnol. Bioeng. 2002, 80 (1), 50-59.
20. Iwatsubo, T.; Odaka, A.; Suzuki, N.; Mizusawa, H.; Nukina, N.; Ihara, Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13 (1), 45-53.
21. Jarrett, J. T.; Berger, E. P.; Lansbury, P. T., Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32 (18), 4693-4697.
22. Andreasen, N.; Hesse, C.; Davidsson, P.; Minthon, L.; Wallin, A.; Winblad, B.; Vanderstichele, H.; Vanmechelen, E.; Blennow, K. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch. Neurol. 1999, 56 (6), 673-680.
23. Ghiso, J.; Calero, M.; Matsubara, E.; Governale, S.; Chuba, J.; Beavis, R.; Wisniewski, T.; Frangione, B. Alzheimer's soluble amyloid beta is a normal component of human urine. FEBS Lett. 1997, 408 (1), 105-108.
24. Hoglund, K.; Wiklund, O.; Vanderstichele, H.; Eikenberg, O.; Vanmechelen, E.; Blennow, K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch. Neurol. 2004, 61 (3), 333-337.
25. Portelius, E.; Westman-Brinkmalm, A.; Zetterberg, H.; Blennow, K. Determination of beta-Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. J. Proteome Res. 2006, 5 (4), 1010-1016.
26. Bibl, M.; Esselmann, H.; Otto, M.; Lewczuk, P.; Cepek, L.; Ruther, E.; Kornhuber, J.; Wiltfang, J. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004, 25 (17), 2912-2918.
27. Maddalena, A. S.; Papassotiropoulos, A.; Gonzalez-Agosti, C.; Signorell, A.; Hegi, T.; Pasch, T.; Nitsch, R. M.; Hock, C. Cerebrospinal Fluid Profile of Amyloid beta Peptides in Patients with Alzheimer's Disease Determined by Protein Biochip Technology. Neurodegenerative Diseases 2004, 1 (4-5), 231-235.
28. Wiltfang, J.; Esselmann, H.; Bibl, M.; Smirnov, A.; Otto, M.; Paul, S.; Schmidt, B.; Klafki, H. W.; Maler, M.; Dyrks, T.; Bienert, M.; Beyermann, M.; Ruther, E.; Kornhuber, J. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 2002, 81 (3), 481-496.
29. Portelius, E.; Zetterberg, H.; Andreasson, U.; Brinkmalm, G.; Andreasen, N.; Wallin, A.; Westman-Brinkmalm, A.; Blennow, K. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci. Lett. 2006, 409 (3), 215-219.
30. Zheng, J.; Li, N.; Ridyard, M.; Dai, H.; Robbins, S. M.; Li, L. Simple and robust two-layer matrix/sample preparation method for MALDI MS/MS analysis of peptides. J. Proteome Res. 2005, 4 (5), 1709-1716.
31. Eckman, E. A.; Reed, D. K.; Eckman, C. B. Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J. Biol. Chem. 2001, 276 (27), 24540-24548.
32. Howell, S.; Nalbantoglu, J.; Crine, P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 1995, 16 (4), 647-652.
33. Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard, N. P.; Gerard, C.; Hama, E.; Lee, H. J.; Saido, T. C. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292 (5521), 1550-1552.
34. Leissring, M. A.; Farris, W.; Chang, A. Y.; Walsh, D. M.; Wu, X.; Sun, X.; Frosch, M. P.; Selkoe, D. J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40 (6), 1087-1093.
35. Oe, T.; Ackermann, B. L.; Inoue, K.; Berna, M. J.; Garner, C. O.; Gelfanova, V.; Dean, R. A.; Siemers, E. R.; Holtzman, D. M.; Farlow, M. R.; Blair, I. A. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20 (24), 3723-3735.
36. Roepstorff, P.; Fohlman, J. Proposal for a common nomenclature for sequence ions in mass spectra of peptides. Biomed. Mass. Spectrom. 1984, 11 (11), 601.